NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Forecast, Price & News $6.06 +0.16 (+2.71%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$5.90▼$6.0850-Day Range$5.90▼$6.9552-Week Range$5.75▼$11.90Volume658,681 shsAverage Volume517,848 shsMarket Capitalization$348.09 millionP/E Ratio20.90Dividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Vanda Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish5.19% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.37Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.44) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector729th out of 983 stocksPharmaceutical Preparations Industry366th out of 486 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vanda Pharmaceuticals. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.19% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 1.78%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 1.9 News and Social Media Coverage News SentimentVanda Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vanda Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions97.22% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to decrease in the coming year, from ($0.44) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is 20.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is 20.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.17.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vanda Pharmaceuticals (NASDAQ:VNDA) StockVanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.Read More Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Stock News HeadlinesJune 4, 2023 | americanbankingnews.comStockNews.com Lowers Vanda Pharmaceuticals (NASDAQ:VNDA) to BuyJune 2, 2023 | msn.comVanda gains on FDA orphan drug designation for nerve disorder candidateJune 4, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...June 1, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2SJune 1, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Presentations at SLEEP 2023May 30, 2023 | bizjournals.comVanda Pharmaceuticals eyeing ‘path forward’ for motion sickness treatmentMay 25, 2023 | finance.yahoo.comA Sea Change in Motion Sickness Therapy: Vanda Pharmaceuticals' Tradipitant Shows Promising Data in Real-world TestMay 25, 2023 | finance.yahoo.comVanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion SicknessJune 4, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 24, 2023 | entrepreneur.com4 Best Biotech Stocks According to POWR RatingsMay 20, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)May 10, 2023 | finance.yahoo.comVanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA AppealMay 4, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Presentations at DDW 2023May 4, 2023 | finance.yahoo.comQ1 2023 Vanda Pharmaceuticals Inc Earnings CallMay 3, 2023 | reuters.comVanda Pharmaceuticals sues US over drug-trade secretsMay 3, 2023 | finance.yahoo.comVanda Pharmaceuticals Reports First Quarter 2023 Financial ResultsMay 2, 2023 | finance.yahoo.comVanda Pharmaceuticals sues U.S. government over drug trade secretsMay 2, 2023 | finance.yahoo.comVanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential InformationApril 27, 2023 | finance.yahoo.comVanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023April 23, 2023 | thestreet.comNovartis to Market Vanda's Fanapt DrugApril 12, 2023 | uk.finance.yahoo.comVanda Pharmaceuticals Inc. (VNDA)April 4, 2023 | finance.yahoo.comCalculating The Fair Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)March 30, 2023 | bizjournals.comVanda Pharmaceuticals wins lawsuit against FDAMarch 28, 2023 | finance.yahoo.comVanda Prevails in Jet Lag Litigation Against the FDAMarch 17, 2023 | prnewswire.comVanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of DirectorsFebruary 26, 2023 | benzinga.comVanda Pharma Stock (NASDAQ:VNDA), Quotes and News SummaryFebruary 10, 2023 | msn.comVanda Pharmaceuticals's Return On Capital Employed InsightsSee More Headlines VNDA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNDA Company Calendar Last Earnings11/03/2021Today6/03/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees278Year Founded2002Profitability EPS (Most Recent Fiscal Year)$0.29 Trailing P/E Ratio20.90 Forward P/E RatioN/A P/E GrowthN/ANet Income$6.28 million Net Margins6.22% Pretax Margin9.50% Return on Equity3.06% Return on Assets2.54% Debt Debt-to-Equity RatioN/A Current Ratio5.69 Quick Ratio5.68 Sales & Book Value Annual Sales$254.38 million Price / Sales1.37 Cash Flow$0.11 per share Price / Cash Flow55.23 Book Value$9.33 per share Price / Book0.65Miscellaneous Outstanding Shares57,440,000Free Float53,423,000Market Cap$348.09 million OptionableOptionable Beta0.68 Social Links Key ExecutivesMihael Hristos PolymeropoulosChairman, President & Chief Executive OfficerKevin MoranChief Financial Officer, Treasurer & SVPTim WilliamsSecretary, Senior VP & General CounselKim WijkstromSenior Vice President & Chief Marketing OfficerGunther BirznieksSenior Vice President-Business DevelopmentKey CompetitorsEmergent BioSolutionsNYSE:EBSRigel PharmaceuticalsNASDAQ:RIGLIntercept PharmaceuticalsNASDAQ:ICPTSpectrum PharmaceuticalsNASDAQ:SPPIVerastemNASDAQ:VSTMView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 4,258 shares on 6/1/2023Ownership: 0.049%Ameriprise Financial Inc.Bought 148,894 shares on 5/22/2023Ownership: 1.725%JPMorgan Chase & Co.Sold 13,412 shares on 5/18/2023Ownership: 0.362%New York State Common Retirement FundBought 33,317 shares on 5/18/2023Ownership: 0.127%Thrivent Financial for LutheransSold 1,772 shares on 5/17/2023Ownership: 0.155%View All Insider TransactionsView All Institutional Transactions VNDA Stock - Frequently Asked Questions How have VNDA shares performed in 2023? Vanda Pharmaceuticals' stock was trading at $7.39 at the beginning of the year. Since then, VNDA stock has decreased by 18.0% and is now trading at $6.06. View the best growth stocks for 2023 here. When is Vanda Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our VNDA earnings forecast. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analyst estimates of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 3.06% and a net margin of 6.22%. During the same period in the prior year, the business posted $0.11 earnings per share. What ETFs hold Vanda Pharmaceuticals' stock? ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Active Factor Small Cap ETF (AFSM), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI). What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX). What is Vanda Pharmaceuticals' stock symbol? Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA." Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.58%), State Street Corp (7.92%), Renaissance Technologies LLC (5.11%), Dimensional Fund Advisors LP (4.85%), Bank of America Corp DE (2.84%) and Pictet Asset Management SA (2.12%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vanda Pharmaceuticals' stock price today? One share of VNDA stock can currently be purchased for approximately $6.06. How much money does Vanda Pharmaceuticals make? Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $348.09 million and generates $254.38 million in revenue each year. The biopharmaceutical company earns $6.28 million in net income (profit) each year or $0.29 on an earnings per share basis. How many employees does Vanda Pharmaceuticals have? The company employs 278 workers across the globe. How can I contact Vanda Pharmaceuticals? Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450. This page (NASDAQ:VNDA) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.